Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.80 +1.6%	$36.73	$23.42 ▼ $62.58	$2.25B	0.8	706,778 shs	700,118 shs
DNLI Denali Therapeutics	$15.49 +1.7%	$14.29	$10.57 ▼ $33.33	$2.26B	1.36	1.42 million shs	2.74 million shs
IDYA IDEAYA Biosciences	$25.12 +2.0%	$22.92	$13.45 ▼ $40.74	$2.20B	0.09	1.14 million shs	850,367 shs
RAPP Rapport Therapeutics	$14.77 -1.1%	$13.70	$6.43 ▼ $29.74	$539.11M	0.62	187,215 shs	182,176 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.75%	+4.14%	-3.68%	+28.19%	-18.90%
DNLI Denali Therapeutics	+4.96%	+5.33%	+9.81%	+13.49%	-39.08%
IDYA IDEAYA Biosciences	+1.27%	+1.07%	+11.85%	+30.87%	-38.01%
RAPP Rapport Therapeutics	+4.26%	-0.07%	-1.78%	+37.99%	-33.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3317 of 5 stars	3.4	2.0	4.3	2.7	0.8	1.9
DNLI Denali Therapeutics	4.204 of 5 stars	3.6	1.0	4.7	3.0	3.3	0.0
IDYA IDEAYA Biosciences	4.519 of 5 stars	4.4	3.0	4.4	3.0	1.7	0.0
RAPP Rapport Therapeutics	1.7637 of 5 stars	3.5	0.0	0.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	45.19% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	117.01% Upside
IDYA IDEAYA Biosciences	2.77	Moderate Buy	$48.09	91.44% Upside
RAPP Rapport Therapeutics	3.00	Buy	$29.50	99.73% Upside

Current Analyst Ratings Breakdown

Latest RAPP, AGIO, DNLI, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/6/2025	RAPP Rapport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$66.00 ➝ $72.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/22/2025	IDYA IDEAYA Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/10/2025	IDYA IDEAYA Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$25.00
7/9/2025	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$57.00 ➝ $30.00
7/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.76	N/A	N/A	$23.57 per share	1.65
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$7.02 per share	N/A
IDYA IDEAYA Biosciences	$7M	314.50	N/A	N/A	$10.95 per share	2.29
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$7.22 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.53	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.79	N/A	N/A	N/A	N/A	-31.42%	-29.45%	11/3/2025 (Estimated)
RAPP Rapport Therapeutics	-$78.31M	-$2.50	N/A	N/A	N/A	N/A	-29.99%	-28.64%	11/6/2025 (Estimated)

Latest RAPP, AGIO, DNLI, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/7/2025	Q2 2025	RAPP Rapport Therapeutics	-$0.87	-$0.75	+$0.12	-$0.75	N/A	N/A
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	-$0.88	-$0.03	-$0.88	$3.48 million	$6.00 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
IDYA IDEAYA Biosciences	N/A	12.39	12.39
RAPP Rapport Therapeutics	N/A	22.75	22.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
IDYA IDEAYA Biosciences	98.29%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DNLI Denali Therapeutics	12.50%
IDYA IDEAYA Biosciences	2.50%
RAPP Rapport Therapeutics	13.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
IDYA IDEAYA Biosciences	80	87.64 million	85.45 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	31.55 million	N/A

RAPP, AGIO, DNLI, and IDYA Headlines

Recent News About These Companies

David Bredt Sells 8,500 Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) Stock

August 20 at 6:18 PM | marketbeat.com

Positive Outlook for Rapport Therapeutics, Inc. Driven by RAP Technology and Strategic Focus on CNS Indications

August 20 at 5:11 AM | tipranks.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Insider Sells $127,500.00 in Stock

August 19 at 4:46 AM | insidertrades.com

HC Wainwright Issues Negative Forecast for RAPP Earnings

August 14, 2025 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Trading Up 7.3% - Time to Buy?

August 13, 2025 | marketbeat.com

Analysts Offer Predictions for RAPP Q2 Earnings

August 9, 2025 | marketbeat.com

Rapport Therapeutics Insider Trading Activity | NASDAQ:RAPP | Benzinga

August 8, 2025 | benzinga.com

Rapport Therapeutics Short Interest Report - Benzinga

August 8, 2025 | benzinga.com

Rapport (RAPP) Q2 Net Loss Widens 47%

August 8, 2025 | aol.comA

Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at HC Wainwright

August 7, 2025 | marketbeat.com

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

August 7, 2025 | globenewswire.com

Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation

August 6, 2025 | msn.com

Rapport Therapeutics initiated with a Buy at H.C. Wainwright

August 6, 2025 | msn.com

Rapport Therapeutics Inc. (RAPP) Stock Price Today - WSJ

July 26, 2025 | wsj.com

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 9.1% - Here's Why

July 25, 2025 | marketbeat.com

AI therapy bots fuel delusions and give dangerous advice, Stanford study finds

July 11, 2025 | arstechnica.comA

Rapport Therapeutics stock rating reiterated as Buy by TD Cowen

July 2, 2025 | uk.investing.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)

...

June 12, 2025 | marketbeat.com

Stifel reiterates buy rating for Rapport Therapeutics stock

June 5, 2025 | uk.investing.com

Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline

June 4, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RAPP, AGIO, DNLI, and IDYA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.80 +0.60 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$38.82 +0.02 (+0.04%)

As of 04:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.49 +0.26 (+1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$15.49 0.00 (0.00%)

As of 04:52 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

IDEAYA Biosciences NASDAQ:IDYA

$25.12 +0.49 (+1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$25.10 -0.02 (-0.06%)

As of 04:20 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Rapport Therapeutics NASDAQ:RAPP

$14.77 -0.16 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$14.76 0.00 (-0.03%)

As of 04:10 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time